SIRT3 and pulmonary arterial hypertension: Of particular interest from a therapeutic standpoint is the finding that the SIRT3 knockout mice and the SIRT3 loss-of-function variant DCM patient both lose the empagliflozin protective effects, since SIRT3 is implicated in many modern world diseases, such as aging, circadian disturbance, pulmonary hypertension, and obesity [25,28].